BR112023001663A2 - Composição farmacêutica compreendendo memantina e citicolina - Google Patents

Composição farmacêutica compreendendo memantina e citicolina

Info

Publication number
BR112023001663A2
BR112023001663A2 BR112023001663A BR112023001663A BR112023001663A2 BR 112023001663 A2 BR112023001663 A2 BR 112023001663A2 BR 112023001663 A BR112023001663 A BR 112023001663A BR 112023001663 A BR112023001663 A BR 112023001663A BR 112023001663 A2 BR112023001663 A2 BR 112023001663A2
Authority
BR
Brazil
Prior art keywords
citicoline
memantine
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR112023001663A
Other languages
English (en)
Inventor
Munirovich Ixanov Rustam
Yurievna Litvinova Elena
Naumovich Leykin Zakhar
Gennadievna Kuznetsova Irina
Khizbullaevich Salakhetdinov Damir
Alekseevna Rogozhkina Elena
Original Assignee
Novamedica Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novamedica Llc filed Critical Novamedica Llc
Publication of BR112023001663A2 publication Critical patent/BR112023001663A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO MEMANTINA E CITICOLINA. A presente invenção refere-se a uma composição farmacêutica com um efeito neuromodulador, antiparkinsoniano, neuroprotetor e antiespástico e destinada ao tratamento de distúrbios cognitivos de origem vascular e compreendendo memantina ou seu sal farmaceuticamente aceitável e citicolina ou seu sal farmaceuticamente aceitável, bem como um método de produção de uma forma de dosagem com base na composição farmacêutica. A atividade terapêutica da citicolina ou seu sal farmaceuticamente aceitável é aumentada devido a um efeito sinérgico quando a citicolina ou seu sal farmaceuticamente aceitável é usado concomitantemente com memantina ou seu sal farmaceuticamente aceitável.
BR112023001663A 2020-07-29 2020-07-29 Composição farmacêutica compreendendo memantina e citicolina BR112023001663A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2020/000389 WO2022025785A1 (ru) 2020-07-29 2020-07-29 Фармацевтическая композиция, включающая мемантин и цитиколин

Publications (1)

Publication Number Publication Date
BR112023001663A2 true BR112023001663A2 (pt) 2023-02-23

Family

ID=80036631

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001663A BR112023001663A2 (pt) 2020-07-29 2020-07-29 Composição farmacêutica compreendendo memantina e citicolina

Country Status (3)

Country Link
EP (1) EP4190319A4 (pt)
BR (1) BR112023001663A2 (pt)
WO (1) WO2022025785A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005201251B2 (en) * 1995-03-06 2006-04-27 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
RS51540B (en) 2004-01-05 2011-06-30 Merz Pharma Gmbh. & Co. Kgaa. MEMANTINE FOR THE TREATMENT OF Mild to Moderate Alzheimer's Disease
RU2404750C2 (ru) 2004-11-23 2010-11-27 Адамас Фармасьютикалс, Инк. Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
RU2390354C2 (ru) 2004-12-27 2010-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Препарат матричного типа с замедленным высвобождением, содержащий основное лекарственное средство или его соль, и способ его получения
RU2436571C2 (ru) 2005-05-23 2011-12-20 Массачусетс Инститьют Оф Текнолоджи Композиции, содержащие полиненасыщенные жирные кислоты (пнжк), и способы их применения
HUE031206T2 (en) 2005-05-23 2017-06-28 Massachusetts Inst Technology Formulations and methods of application containing PUFA
RU2326660C1 (ru) 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
RU2483715C2 (ru) 2010-12-30 2013-06-10 Общество с ограниченной ответственностью "АКАДЕМФАРМ" Твердая лекарственная форма препаратов мемантина и его солей
EP2884967B1 (en) * 2012-08-16 2017-02-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
RU2605339C2 (ru) * 2013-07-23 2016-12-20 Закрытое акционерное общество "ЭкоФармПлюс" Средство для купирования глутамат-индуцированного апоптоза и ингибирования nmda-рецепторов, обладающее иммуномодулирующим действием, для лечения расстройств нервной системы, последствий черепно-мозговой травмы и ишемического и геморрагического инсульта
RU2564008C2 (ru) * 2013-09-26 2015-09-27 Закрытое акционерное общество "ЭкоФармПлюс" Фармацевтическая композиция, обладающая противогипоксической, нейропротекторной и антимнестической активностью и повышающая физическую работоспособность

Also Published As

Publication number Publication date
WO2022025785A1 (ru) 2022-02-03
EP4190319A4 (en) 2024-05-01
WO2022025785A8 (ru) 2022-04-21
EP4190319A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR090601A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos
BR112012006010A2 (pt) composto de glicina
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
BR112021017203A2 (pt) Leucina, acetil leucina e análogos relacionados para o tratamento de doenças
BR112017010601A2 (pt) análogos de ureia substituídos em ponte como moduladores de sirtuínas
BR112015019919A2 (pt) compostos bicíclicos
BR112021018591A2 (pt) Compostos e usos dos mesmos
BR112023023030A2 (pt) Composições e métodos para o tratamento de depressão
BR112023001663A2 (pt) Composição farmacêutica compreendendo memantina e citicolina
BR112022010733A2 (pt) Métodos para tratar dor
BR112015009504A2 (pt) inibidores de rock
MX2020005809A (es) Composicion topica oftalmica para tratar enfermedades del segmento posterior del ojo.
AR077123A1 (es) Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]